The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Athersys Inc.

  • ATHX
  • NASDAQ
  • Consumer Products
  • Latest 1.41
  • Currency US$
  • Change 0.03
  • Percent Change 2.174 %
  • Volume 271,450
  • Fri Aug 29, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 1.38
  • Previous Close 1.38
  • High 1.42
  • Low 1.37
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High01/09 4.33
  • 52-week Low04/28 1.08
  • Beta 1.208
  • Market Cap 108.05M
  • EPS -0.44
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Press Releases

Financials & Calendars

Income Statement

  • Sales $2,820,000
  • Earnings $-32,840,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $44,980,000
  • Current Ratio 10.84

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $47,580,000
  • Liabilities $17,920,000
  • Liabilities-to-Equity Ratio 0.60

Price Ratios

  • Price to Sales 38.32
  • Price to Book 3.64
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Aug 11 $-0.09 Nov 13 $-0.09
Surprises Aug 11 -33.33% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Aug 31, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.

Related Securities
Symbol Type Latest % Chg

Officers

  • Gil Van Bokkelen Chmn; C.E.O. & Dir
  • John J. Harrington Exec V.P.; Chief Scientific Of
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

3201 CARNEGIE AVENUE
CLEVELAND, OH
44115-2

Phone: (216)-431-9900
Fax: (216)-3619495

ir@athersys.com
www.athersys.com

Ideas & Discussion

Live Discussion of ATHX on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.